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Abstract A major issue concerning clinical trials is the
availability of standardized assays to evaluate drug efficacy.
Ideally, such assays should test the effect of a putative drug
on the expression of a biomarker in biological fluids. In a
recent study by Kuiper et al. (PLOS One, 3(7): e2675). The
relative levels of vascular endothelial growth factor (VEGF)
and CCN2 (connective tissue growth factor [CTGF]) were
examined in proliferative diabetic retinopathy (PDR). This
paper is the subject of this commentary.
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Problems involving clinical trials for chronic fibroprolifer-
ative disease are the long duration of the trial (due to
relatively slow disease progression) and difficult-to-detect
endpoints that may not be successfully standardized from
center to center. The availability of a relatively inexpensive,
easy-to-perform assay with high signal-to-noise ratio would
be highly beneficial.
CCN2, a cysteine-rich secretory protein of 36 to 38 kDa
that has four distinct modules, is largely regulated at the
level of gene transcription (Blom et al. 2002). CCN2 is
characteristically overexpressed in a wide variety of fibrotic
disorders, and thus may represent an ideal surrogate
biomarker for these diseases (Leask et al. 2009).
Blindness from proliferative diabetic retinopathy (PDR)
is caused by angiogenesis and fibrosis in the vitreous cavity
of the eye. In this condition, neovascularization is accom-
panied by inflammation and fibrosis, and the appearance of
myofibroblasts (Fong et al. 2004). There is no treatment for
PDR.
In a recent report, Kuiper et al. (2008) used ELISAs to
monitor the expression of CCN2 and VEGF proteins in the
vitreous of PDR patients. CCN2 levels were using
sandwich ELISAs, using two distinct monoclonal anti-
bodies specifically recognizing the N-terminal part of the
CCN2 (FibroGen). VEGF165 levels were also determined
by means of sandwich ELISA a (R&D Systems). Vitreous
CCN2 levels were significantly associated with degree of
fibrosis and with VEGF levels, but not with neovasculari-
zation, whereas VEGF levels were associated only with
neovascularization. The ratio of CCN2 to VEGF was the
strongest predictor of degree of fibrosis.
To my knowledge, no study has examined both the
levels of CCN2 and VEGF in a fibroproliferative condition.
These data provide an exciting insight not only into the
basis for fibrogenesis in the eye, but also open up the
thrilling possibility, from a clinical perspective, of being
able in the future to effectively monitor disease progression
and drug efficacy in clinical trials. The next goal presum-
ably would be to widely test these ideas in a variety of
longitudinal trials, in pilot studies with actual compounds,
and in other systems.
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